Enara Bio banked €48.8M ($53M) Series B funding to advance its pipeline of cancer immunotherapies. The investment supports the continued development of the company’s proprietary platform, which identifies Dark Antigen targets derived from the genomic "dark matter" of the human genome.
The London-based biotech company focuses on discovering T-cell receptor (TCR) based therapies. By exploring non-coding regions of DNA that are typically overlooked, Enara Bio seeks to find tumor-specific markers that are shared across different patients, potentially allowing for the treatment of broader cancer populations.
This latest capital injection follows the company’s efforts to decode the immune system’s response to various cancers using specialized analytical techniques. The platform processes biological data to reveal how the immune system interacts with hidden genomic sequences, providing a map for the development of next-generation biologics.
The raise highlights the sustained appetite for high-science UK biotechnology firms that integrate genomic discovery with clinical therapy development.
Originally reported by Tech Funding News.